Anna Eramo resigned as Chief Medical Officer at LB PHARMACEUTICALS INC.
“On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").”
LB PHARMACEUTICALS INC — fact timeline
Source-grounded facts extracted from LB PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LB PHARMACEUTICALS INC shareholders approved Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
LB PHARMACEUTICALS INC shareholders approved Election of Class I Directors to serve three-year terms until 2029 at the 2026-06-03 meeting.
“The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal.”
LB PHARMACEUTICALS INC reported financial results for the first quarter ended on March 31, 2026.
“On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
LB PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2025.
“On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025.”
LB PHARMACEUTICALS INC issued pre-funded warrants to purchase up to 1,417,107 shares of warrant to institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners) for $21.1699 per pre-funded warrant.
“to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such”
LB PHARMACEUTICALS INC issued 3,306,571 shares of common stock to institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners) for $21.17 per share.
“to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such”
LB PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain investors valued at approximately $100.0 million (effective 2026-02-04).
“On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,417,107 shares of Common Stock”
LB PHARMACEUTICALS INC: Adopted amended and restated bylaws effective upon closing of IPO (effective 2025-09-12).
“Effective as of September 12, 2025, the Company adopted amended and restated bylaws (the “ Restated Bylaws ”) in connection with the closing of the IPO”
LB PHARMACEUTICALS INC: Filed amended and restated certificate of incorporation effective upon closing of IPO (effective 2025-09-12).
“the Company filed an amended and restated certificate of incorporation (the “ Restated Certificate ”) with the Secretary of State of the State of Delaware”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.